This company has been marked as potentially delisted and may not be actively trading. NASDAQ:APGE Apogee Therapeutics (APGE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsInsider TradesNews and TrendsOwnershipShort Interest About Apogee Therapeutics Stock (NASDAQ:APGE) Get Apogee Therapeutics alerts:Sign Up Key Stats Today's Range$135.07▼$135.0750-Day Range$134.09▼$135.1052-Week Range$35.39▼$135.09VolumeN/AAverage Volume1.39 million shsMarket Capitalization$8.40 billionP/E RatioN/ADividend YieldN/APrice Target$126.77Consensus RatingHold Company Overview Apogee Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation biologic medicines for inflammatory and immunologic diseases. The company’s approach emphasizes therapies designed to offer extended dosing intervals, with the goal of improving convenience and treatment options for patients with chronic conditions. Apogee’s lead program is APG777, a long-acting monoclonal antibody that targets interleukin-13 (IL-13), a cytokine involved in allergic inflammation. The program is being developed for conditions including atopic dermatitis, asthma and other inflammatory diseases. The company is also advancing APG808, an extended-half-life antibody targeting the interleukin-4 receptor alpha (IL-4Rα) pathway, which is implicated in several type 2 inflammatory disorders. Apogee was established in 2022 and became a publicly traded company on the Nasdaq under the symbol APGE in 2023. The company is headquartered in San Francisco, California, and its development activities are focused on addressing unmet needs in inflammatory and immunologic diseases. Apogee is led by Chief Executive Officer Michael Henderson.AI Generated. May Contain Errors. Read More Receive APGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apogee Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. APGE Stock News Headlines4 Elite Dividend Stocks That Pay You Passive Income Every QuarterNovember 2, 2026 | 247wallst.comParagon Labs Adds Former Apogee Leaders As Alaunos Completes Velaris Acquisition; Stock UpOctober 13, 2026 | rttnews.comI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 19 at 1:00 AM | Behind the Markets (Ad)Apogee Therapeutics, Inc.(NasdaqGM:APGE) dropped from S&P Global BMI IndexSeptember 3, 2026 | marketscreener.comMAbbVie Closes $10.9 Billion Acquisition of Apogee TherapeuticsSeptember 3, 2026 | finance.yahoo.comApogee Therapeutics, Inc.(NasdaqGM:APGE) dropped from S&P Biotechnology Select Industry IndexSeptember 3, 2026 | marketscreener.comMAbbVie Completes $10.9 Bln Acquisition Of Apogee TherapeuticsSeptember 3, 2026 | rttnews.comAbbVie seals $11B acquisition of Apogee TherapeuticsSeptember 3, 2026 | msn.comSee More Headlines APGE Stock Analysis - Frequently Asked Questions How were Apogee Therapeutics' earnings last quarter? Apogee Therapeutics Inc. (NASDAQ:APGE) issued its quarterly earnings results on Monday, August, 10th. The company reported ($1.14) EPS for the quarter, missing analysts' consensus estimates of ($1.07) by $0.07. When did Apogee Therapeutics IPO? Apogee Therapeutics (APGE) raised $282 million in an initial public offering on Thursday, July 13th 2023. The company issued 17,650,000 shares at $15.00-$17.00 per share. What other stocks do shareholders of Apogee Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Apogee Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Atai Beckley (ATAI), BridgeBio Pharma (BBIO), Corbus Pharmaceuticals (CRBP), DraftKings (DKNG) and Exelixis (EXEL). Company Calendar Last Earnings8/10/2026Today11/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (16m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 APGE's financial health is in the Green zone, according to TradeSmith. APGE has been in this zone for over 16 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:APGE CIK1974640 Webwww.apogeetherapeutics.com Phone650-394-5230FaxN/AEmployees91Year FoundedN/APrice Target and Rating Average Price Target for Apogee Therapeutics$126.77 High Price Target$160.00 Low Price Target$89.00 Potential Upside/Downside-6.1%Consensus RatingHold Rating Score (0-4)2.16 Research Coverage19 Analysts Profitability EPS (Trailing Twelve Months)($4.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$255.84 million Net MarginsN/A Pretax MarginN/A Return on Equity-29.88% Return on Assets-28.08% Debt Debt-to-Equity RatioN/A Current Ratio26.44 Quick Ratio26.44 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$19.21 per share Price / Book7.03Miscellaneous Outstanding Shares62,201,000Free Float47,086,000Market Cap$8.40 billion OptionableOptionable Beta0.33 Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:APGE) was last updated on 9/4/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredAlpha Oracle Signal drops to $7 for Black FridayThe Alpha Oracle Signal trading system is on sale for just $7 during a limited Black Friday deal. Others paid ...TradeWins | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apogee Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.